The prognostic value of HER2 in ovarian cancer:a meta-analysis of observational studies

doi:10.26914/c.cnkihy.2018.030892

科研成果详情

题名	The prognostic value of HER2 in ovarian cancer:a meta-analysis of observational studies
作者	Hui Luo ; Xiaohui Xu ; Miaomiao Chen ; Bo Sheng ; Xueqiong Zhu
发表日期	2018-11-22
会议录名称	2018年浙江省妇科肿瘤学学术年会暨温台妇产科年会论文汇编影响因子和分区
语种	英语
原始文献类型	中国会议
摘要	Background:Ovarian cancer is the leading cause of gynecologic cancer death in women and impacts female life and health all over the world.Hence,it is of great clinical value to identify applicable prognosis biomarkers to predict the outcomes of ovarian cancer patients.Human epidermal growth factor receptor 2(HER2) is a tyrosine kinase receptor in the epidermal growth factor(EGF) family and play a pivotal role in cell proliferation and tumor cell metastasis.HER2 overexpression has been detected in various cancer types.Until now,the prognostic role of human epidermal growth factor receptor 2(HER2) in ovarian cancer has been investigated in previous studies,but the results remain controversial.Here we present a meta-analysis to systematically review the association between HER2 expression and ovarian cancer prognosis.Method:Observational studies published from 1980 to July 2017 were comprehensively searched in Pubmed,Embase,and Cochrane library databases with following keywords:"ovarian cancer","ovarian tumor","ovarian neoplasm","ovarian carcinoma" or ovarian malignance" and "HER2","HER-2","HER 2","human epidermal growth factor receptor 2","erbB-2" or "neu" and "prognosis","survival" and "outcome".All candidate studies were carried out by two independent reviewers.Studies that fulfilled the following criteria were considered eligible and selected into this article:the publication explored the relation between HER2 expression and ovarian cancer prognosis,such as overall survival(OS),progress-free survival(PFS),disease-free survival(DFS) and recurrence-free survival(RFS);sufficient data were either reported directly or there was sufficient data to calculate HR with 95% confidence interval(CI);studies were written in English;exclusion of reviews,letters to the editor,case reports and conference papers without original data.MetaHR and95% CI were applied to assess the association between HER2 expression and outcomes of ovarian cancer patients(OS and DFS/PFS).Statistical heterogeneity was assessed by H and I-square statistics,random-effects model was used in the paper.Subgroup analysis and sensitivity analysis were performed to explore the source of heterogeneity.Publication bias was evaluated by a funnel plot with Begg's test,Statistical analyses were conducted Stata version12.0(StataCrop LP,Texas).Result:Thirty-four studies that include 5180 ovarian cancer patients were finally collected for analysis.Expression of HER2 was negatively correlated with clinical prognosis of overall survival(HR=1.57,95% CI:1.31 to 1.89,P <0.001) and disease-free survival/progress-free survival(HR=1.26,95%CI=1.06 to 1.49) in ovarian cancers.The association between HER2 expression and poor ovarian cancer prognosis in overall survival was also statistically significant in subgroups of unclassified ovarian cancer(n=30,HR=1.55,95% CI=1.29 to 1.88),Caucasian population(n=26,HR=1.59,95% CI=1.3 to 1.94) and Asian population(n=6,HR=1.75,95% CI=1.06 to 2.9),while irrespective of immunohistochemistry(IHC) method(n=27,HR=1.59,95% CI=1.28 to 1.98) and other detection Methods(n=7,HR=1.47,95% CI=1.06 to 2.04).In addition,HER2 was an unfavorable predictor of DFS/PFS in subgroups of unclassified ovarian cancer(n=11,HR=1.34,95% CI=1.08 to 1.67),Caucasian populations(n=10,HR=1.32,95% CI=1.07 to 1.63) and IHC detection method(n=12,HR=1.26,95% CI=0.99 to 1.6). Conclusion:HER2 may be a potential marker to predict the poor prognosis of ovarian cancer patients,especially for patients with unclassified ovarian cancer and Caucasian region.Additionally,immunohistochemistry is an effective method for predicting ovarian cancer clinical outcomes when evaluate HER2 expression.
页码	2
DOI	10.26914/c.cnkihy.2018.030892
收录类别	CNKI
引用统计
文献类型	会议论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/167836
专题	第二临床医学院，附属第二医院、育英儿童医院
作者单位	1.Department of Obstetrics and Gynecology 2.the Second Affiliated Hospital of Wenzhou Medical University
推荐引用方式 GB/T 7714	Hui Luo,Xiaohui Xu,Miaomiao Chen,et al. The prognostic value of HER2 in ovarian cancer:a meta-analysis of observational studies[C],2018:2.